XFOR Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2016βFY2025
X4 Pharmaceuticals, Inc had $6.5M of revenue in fiscal 2025, up 150.0% on the year before. Over five years, revenue changed +16.7% a year on average.
Last close Β· Oct 23, 2026
$3.24
1.3%Hi! I read X4 Pharmaceuticals, Incβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+150.0%
Yes. Sales grew 150.0% last year.
Does it make a profit?
β1,218.4%
No. It lost money last year.
Does profit turn into cash?
β1,317.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
2.6x
One share costs 2.6 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days X4 Pharmaceuticals, Inc did it, and the next one. Share prices often move a lot on those days.
Next results
November 4, 2026
Wednesday Β· in 9 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 6, 2026 | Q2 '26 | After the market closes | 10-Q β |
| May 6, 2026 | Q1 '26 | Before the market opens | 10-Q β |
| Mar 17, 2026 | Q4 '25 | Before the market opens | 10-K β |
| Nov 5, 2025 | Q3 '25 | Before the market opens | 8-K β |
| Aug 8, 2025 | Q2 '25 | After the market closes | 10-Q β |
| May 1, 2025 | Q1 '25 | Before the market opens | 8-K β |
| Mar 25, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Nov 13, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· X4 Pharmaceuticals, Inc had $6.5M of revenue in fiscal 2025, up 150.0% on the year before. Over five years, revenue changed +16.7% a year on average. Its operating margin was β1,336.7%, up 63.4Β pts: of every 100 in sales, about β1,337 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· X4 Pharmaceuticals, Inc lost $79.2M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$85.6M in fiscal 2025, β1,317.2% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· X4 Pharmaceuticals, Inc has $142M more cash than debt.
Cash, debt and the ratios that show how comfortably X4 Pharmaceuticals, Inc can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $81.8M | $122M | $99.2M | $55.7M | $217M |
| Debt incl. finance leases | $32.5M | $32.5M | $55.0M | $75.0M | $75.0M |
| Debt / equity | 0.5x | 0.4x | 1.1x | 3.4x | 0.4x |
| Interest coverage | β23.4x | β21.9x | β18.6x | β4.2x | β9.8x |
| Current ratio | 6.3x | 5.8x | 5.3x | 3.4x | 10.2x |
| Quick ratio | 6.3x | 5.8x | 5.3x | 3.3x | 10.2x |
| Total assets | $117M | $156M | $147M | $146M | $290M |
| Total liabilities | $52.8M | $81.5M | $96.2M | $124M | $104M |
| Shareholders' equity | $64.4M | $74.1M | $51.1M | $22.1M | $186M |
| Net debt (β = net cash) | β$49.3M | β$89.2M | β$44.2M | $19.3M | β$142M |
KIRA Β· Its return on capital was β155.1%: every 100 invested in the business earned about β155 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· X4 Pharmaceuticals, Inc passes 3 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 4 | β / 6 | 4 / 8 | 2 / 8 | 1 / 8 | 3 / 8 | 2 / 8 | 2 / 8 | 3 / 9 |
| Accruals ratio | β | β0.8% | β17.2% | β5.6% | β2.3% | β14.8% | β12.3% | β3.1% | 63.6% | 2.9% |
| Altman Z'' | β | β2.06 | β48.43 | 4.36 | β3.09 | β7.33 | β6.24 | β10.51 | β9.40 | β1.48 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | β | β | $0.0M | $0.0M | $3.0M | $0.0M | $0.0M | $0.0M | $2.6M | $6.5M |
| Gross profit | β | β | β | β | β | β | $0.0M | $0.0M | $1.8M | $0.7M |
| Research and development | $17.8M | $17.1M | $20.3M | $30.2M | $41.9M | $50.6M | $61.1M | $72.0M | $81.6M | $72.7M |
| Operating income | β$24.3M | β$22.2M | β$29.1M | β$51.7M | β$59.9M | β$85.1M | β$87.6M | β$108M | β$36.4M | β$86.9M |
| Interest expense | $2.5M | $0.5M | $0.7M | $2.1M | $2.7M | $3.6M | $4.0M | $5.8M | $8.8M | $8.9M |
| Pretax income | β$23.0M | β$22.0M | β$33.3M | β$52.8M | β$62.0M | β$88.7M | β$93.8M | β$101M | β$37.1M | β$79.2M |
| Income tax | β | β | $0.0M | $0.0M | $0.1M | $0.0M | $0.0M | $0.1M | $0.3M | $0.0M |
| Net income | β$23.0M | β$22.0M | β$33.3M | β$52.8M | β$62.1M | β$88.7M | β$93.9M | β$101M | β$37.5M | β$79.2M |
| Net income to common | β$23.0M | β$25.0M | β$36.3M | β$53.4M | β$62.1M | β$103M | β$96.4M | β$101M | β$37.5M | β |
| Diluted EPS | β$44.79 | β$54.58 | β$79.15 | β$4.63 | β$3.09 | β$3.99 | β$1.52 | β$17.07 | β$5.59 | β$1.87 |
| Diluted shares | 0.00B | 0.00B | 0.00B | 0.01B | 0.02B | 0.03B | 0.06B | 0.01B | 0.01B | 0.04B |
| Cash flow | ||||||||||
| Cash from operations | β$21.6M | β$21.3M | β$25.4M | β$48.1M | β$58.8M | β$70.9M | β$77.1M | β$96.5M | β$131M | β$85.6M |
| Capital expenditure | $0.1M | $0.4M | $0.0M | $0.2M | $1.4M | $0.6M | $0.1M | $0.1M | $0.3M | $0.0M |
| Free cash flow | β$21.7M | β$21.7M | β$25.4M | β$48.2M | β$60.2M | β$71.5M | β$77.2M | β$96.6M | β$131M | β$85.6M |
| Depreciation and amortization | $0.3M | $0.1M | $0.1M | $0.1M | $0.4M | $0.5M | $0.5M | $0.4M | $0.8M | $1.3M |
| Stock-based compensation | $0.6M | $0.5M | $0.8M | $2.1M | $5.4M | $6.2M | $5.2M | $8.7M | $8.2M | $4.3M |
| Share buybacks | β | β | β | $0.0M | $0.0M | $2.0M | $0.0M | $0.0M | β | β |
| Dividends and buybacks | β | β | β | $0.0M | $0.0M | $2.0M | $0.0M | $0.0M | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $15.2M | $26.7M | $8.1M | $126M | $78.7M | $81.8M | $122M | $99.2M | $55.7M | $217M |
| Total debt | β | β | $10.0M | $20.0M | $32.5M | $32.5M | $32.5M | $55.0M | $75.0M | $75.0M |
| Current assets | β | $79.5M | $9.3M | $129M | $83.3M | $87.9M | $129M | $122M | $112M | $262M |
| Current liabilities | β | $10.7M | $7.9M | $9.4M | $11.9M | $14.0M | $22.3M | $22.9M | $32.9M | $25.8M |
| Inventory | β | β | β | β | β | β | β | $0.0M | $2.8M | β |
| Property and equipment, net | β | $0.4M | $0.2M | $0.4M | $1.2M | $1.5M | $1.1M | $0.7M | $0.8M | $0.2M |
| Goodwill | β | β | $0.0M | $27.1M | $27.1M | $17.4M | $17.4M | $17.4M | $17.4M | $17.4M |
| Intangible assets | β | β | β | β | β | β | β | $0.0M | $10.0M | $9.3M |
| Total assets | β | $81.3M | $9.9M | $161M | $123M | $117M | $156M | $147M | $146M | $290M |
| Total liabilities | β | $22.5M | $21.6M | $31.5M | $50.1M | $52.8M | $81.5M | $96.2M | $124M | $104M |
| Preferred stock | β | β | β | β | β | β | β | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | β$23.1M | β$44.5M | β$77.1M | $129M | $72.8M | $64.4M | $74.1M | $51.1M | $22.1M | $186M |
| Margins | ||||||||||
| Gross margin | β | β | β | β | β | β | β | β | 69.3% | 11.4% |
| Operating margin | β | β | β | β | β1,995.8% | β | β | β | β1,400.0% | β1,336.7% |
| EBITDA margin | β | β | β | β | β1,984.1% | β | β | β | β1,369.4% | β1,317.0% |
| Net margin | β | β | β | β | β2,071.0% | β | β | β | β1,440.4% | β1,218.4% |
| FCF margin | β | β | β | β | β2,006.0% | β | β | β | β5,047.2% | β1,317.2% |
| Returns | ||||||||||
| Return on capital | β | β | β | β177.3% | β177.9% | β444.5% | β | β1,234.1% | β69.4% | β155.1% |
| Return on capital employed | β | β31.5% | β1,427.8% | β34.2% | β54.0% | β82.5% | β65.7% | β86.4% | β32.1% | β32.8% |
| Return on equity | β | β | β | β202.6% | β61.5% | β129.3% | β135.6% | β161.7% | β102.3% | β76.0% |
| Return on assets | β | β27.1% | β73.0% | β61.9% | β43.8% | β73.9% | β68.8% | β66.8% | β25.5% | β36.3% |
| Return on tangible equity | β | β | β | β52.3% | β136.0% | β218.1% | β170.0% | β299.8% | β | β49.6% |
| Growth | ||||||||||
| Revenue growth | β | β | β | β | β | β100.0% | β | β | β | 150.0% |
| Share count change | β | β10.8% | 0.2% | 2,412.0% | 74.1% | 28.3% | 146.7% | β90.7% | 13.1% | 531.0% |
| Financial health | ||||||||||
| Debt / equity | β | β | β | 0.2x | 0.4x | 0.5x | 0.4x | 1.1x | 3.4x | 0.4x |
| Interest coverage | β9.7x | β45.4x | β40.4x | β24.1x | β22.3x | β23.4x | β21.9x | β18.6x | β4.2x | β9.8x |
| Current ratio | β | 7.4x | 1.2x | 13.7x | 7.0x | 6.3x | 5.8x | 5.3x | 3.4x | 10.2x |
| Quick ratio | β | 7.4x | 1.2x | 13.7x | 7.0x | 6.3x | 5.8x | 5.3x | 3.3x | 10.2x |
| Capital allocation | ||||||||||
| Capex / revenue | β | β | β | β | 45.4% | β | β | β | 12.5% | 0.0% |
| Stock comp / revenue | β | β | β | β | 180.9% | β | β | β | 315.5% | 66.1% |
| Quality scores | ||||||||||
| Piotroski F-score | β | β | β | 4.0 | 2.0 | 1.0 | 3.0 | 2.0 | 2.0 | 3.0 |
| Altman Z'' | β | β2.1 | β48.4 | 4.4 | β3.1 | β7.3 | β6.2 | β10.5 | β9.4 | β1.5 |
| Accruals ratio | β | β0.8% | β17.2% | β5.6% | β2.3% | β14.8% | β12.3% | β3.1% | 63.6% | 2.9% |
Source: SEC EDGAR XBRL filings (CIK 0001501697). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
